Skip to main content
. Author manuscript; available in PMC: 2015 Jan 21.
Published in final edited form as: FEBS Lett. 2013 Nov 14;588(2):334–340. doi: 10.1016/j.febslet.2013.11.007

Figure 3. Using engineered knob proteins to enhance killing of lymphoma cells.

Figure 3

Panel A – Experimental setup. Lymphoma cells were incubated with the engineered knob protein Ad35K++ as reported in Wang et al. [82]. NHS is used as source of complement. Panel B – Both research and scaled preparations have equivalent efficacy. N>6. Ad35K++ (1) is a protein lot that was produced previously and used in published studies. Ad35K++ (2) is a protein made with a scalable process. The difference between rituximab + NHS and Ad35K++ + rituximab + NHS is significant (p<0.01). The difference between Ad35K++ (1) + rituximab + NHS and Ad35K++ (2) + rituximab + NHS is not significant.